Characteristics of individuals with cystic fibrosis in the United States ineligible for ivacaftor and elexacaftor/tezacaftor/ivacaftor
Don B. Sanders(Indiana University School of Medicine), Elizabeth A. Cromwell(University of Washington), Rhonda D. Szczesniak(Cincinnati Children's Hospital Medical Center), Nicole Mayer-Hamblett(Seattle Children's Hospital), Margaret Rosenfeld(Seattle Children's Hospital), Elliott C. Dasenbrook(Cleveland Clinic), Deepika Polinieni(Washington University in St. Louis)
Cited by 11
Related Papers
Effect of VX-770 in Persons with Cystic Fibrosis and the G551D- <i>CFTR</i> Mutation
|New England Journal of Medicine|2010|802
Control of Confounding and Reporting of Results in Causal Inference Studies. Guidance for Authors from Editors of Respiratory, Sleep, and Critical Care Journals
|Annals of the American Thoracic Society|2018|723
Persistent Methicillin-resistant <i>Staphylococcus aureus</i> and Rate of FEV1 Decline in Cystic Fibrosis
|American Journal of Respiratory and Critical Care Medicine|2008|322